For Relapsed or Refractory Multiple Myeloma

  FDA Approves Daratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma – The ASCO Post New treatment strategies available for patients with multiple myeloma who have received at least one prior therapy. Daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone has been FDA approved.   Quelle: FDA […]

Read More For Relapsed or Refractory Multiple Myeloma

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. – PubMed – NCBI

Glioblastoma is the most progressive brain tumor with a dismal prognosis. One strategy is to target a novel and highly specific tumor antigen, EGFR variant III. This tumor antigen is present in approx. a third of all patients with GBM and is exclusively expressed on tumor tissue cells. Eur J Pharmacol. 2017 Sep 5;810:70-82. doi: […]

Read More The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. – PubMed – NCBI

FDA Approves Panitumumab for Use in Wild-Type RAS Metastatic Colorectal Cancer – The ASCO Post

Panitumumab now approved for wild-type Ras metastatic colorectal cancer. Along with this, the FDA approved the first multigene, next-generation sequencing-based test to identify the RAS mutation status of a patient’s tumor tissue designed to help identify patients that are more likely to benefit from treatment with panitumumab. This highlights how important analysis of tumor tissue […]

Read More FDA Approves Panitumumab for Use in Wild-Type RAS Metastatic Colorectal Cancer – The ASCO Post